|
|
Volumn 44, Issue 15, 2008, Pages 2162-2168
|
|
Open-label, non-randomised, inter-individual dose escalation of ZK 304709 with the evaluation of safety, tolerability, pharmacokinetics, oral bioavailability and orientating efficacy after daily administration in patients with advanced cancer (7 d treatment and 14 d recovery)
a
|
|
Author keywords
Angiogenesis inhibitor; Apoptosis induction; Cell cycle arrest; Phase I; ZK 304709
|
|
Indexed keywords
ANTIEMETIC AGENT;
ANTIHYPERTENSIVE AGENT;
BIOLOGICAL MARKER;
GROWTH INHIBITOR;
UNCLASSIFIED DRUG;
WARFARIN;
ZK 304709;
ADULT;
ADVANCED CANCER;
ALOPECIA;
ANOREXIA;
AREA UNDER THE CURVE;
ARTICLE;
BLOOD SAMPLING;
BLOOD TOXICITY;
CANCER INHIBITION;
CLINICAL ARTICLE;
CLINICAL TRIAL;
COMPUTER ASSISTED TOMOGRAPHY;
DIARRHEA;
DIZZINESS;
DRUG BIOAVAILABILITY;
DRUG BLOOD LEVEL;
DRUG DOSE ESCALATION;
DRUG EFFICACY;
DRUG FATALITY;
DRUG MECHANISM;
DRUG SAFETY;
DRUG TOLERABILITY;
ELECTROCARDIOGRAM;
FATIGUE;
FEBRILE NEUTROPENIA;
FEMALE;
GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL;
GASTROINTESTINAL HEMORRHAGE;
HEMOGLOBIN BLOOD LEVEL;
HUMAN;
HYPERTENSION;
HYPOPHOSPHATEMIA;
INTERNATIONAL NORMALIZED RATIO;
LABORATORY TEST;
LETHARGY;
LIQUID CHROMATOGRAPHY;
LYMPHOCYTOPENIA;
MALE;
MASS SPECTROMETRY;
MAXIMUM PLASMA CONCENTRATION;
MAXIMUM TOLERATED DOSE;
MULTICENTER STUDY;
NAUSEA AND VOMITING;
NEUTROPENIA;
PHASE 1 CLINICAL TRIAL;
PRIORITY JOURNAL;
SCREENING;
SIDE EFFECT;
SOLID TUMOR;
STANDARD;
SUPRAVENTRICULAR TACHYCARDIA;
THROMBOCYTOPENIA;
TREATMENT RESPONSE;
TUMOR CLASSIFICATION;
ADULT;
AGED;
ANGIOGENESIS INHIBITORS;
ANTINEOPLASTIC AGENTS;
BIOLOGICAL AVAILABILITY;
DISEASE PROGRESSION;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG ADMINISTRATION SCHEDULE;
FEMALE;
HUMANS;
MALE;
MAXIMUM TOLERATED DOSE;
MIDDLE AGED;
NEOPLASMS;
PATIENT SELECTION;
PROTEIN KINASE INHIBITORS;
TREATMENT OUTCOME;
|
|
EID: 53249100318
PISSN: 09598049
EISSN: None
Source Type: Journal
DOI: 10.1016/j.ejca.2008.06.006 Document Type: Article |
|
Times cited : (15)
|
|
References (6)
|
